CA: Administrative Core

CA：行政核心

• 批准号: 7510676
• 负责人: SCOTT M LIPPMAN
• 金额: $ 10.64万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7510676
• 关键词: Achievement; Address; Advisory Committees; Award; Biological Markers; Biometry; Budgets; Cancer Center; Clinical; Clinical Trials; Closure; Collaborations; Communication; Consultations; Data; Development; Discipline; Employment; Ensure; Funding; Goals; Grant; Head and Neck Cancer; Human Resources; Laboratories; Leadership; Minority; Monitor; National Cancer Institute; Organ; Pathology; Policies; Preparation; Procedures; Process; Publications; Quality Control; Regulation; Reporting; Reproduction spores; Research; Research Personnel; Resources; Risk; Role; Schedule; Site; Tissue Procurements; Translations; United States National Institutes of Health; Woman; anticancer research; base; career; clinical application; cost; data management; experience; falls; interdisciplinary approach; lectures; programs; success; symposium

Core A is essential to the success of the SPORE and provides oversight and support of all SPORE projects and activities; ensures compliance with all general, governmental, and National Cancer Institute (NCI)/National Institutes of Health (NIH) regulations and requirements; coordinates communications and consultations with the NCI project officer and other NCI staff in preparing all required reports and publications; coordinates all SPORE-related meetings and communications of the Executive Committee, Internal and External Advisory Boards, the Biostatistics and Data Management Core (Core B), and the Tissue Procurement, Pathology and Biomarker Core (Core C); and other key functions. Over the previous grant period, Core A oversaw the annual budget/rebudget development, distribution, and oversight of grant funds; supported the Executive Committee and advisory boards in scheduling and coordinating regularly scheduled meetings and ad hoc consultations; coordinated the annual solicitation, review, and award process for the Career Development and the Developmental Research Programs; served as the primary liaison in developing potential InterSPORE collaborations and with the NCI SPORE program representatives; and interacted on a regular basis with Core Directors and Project Leaders to review progress, identify problems, and resolve issues hampering successful achievement of their aims. The past trial activation and accrual record of this HN SPORE was the appropriate target of criticism in our previous review; thus, the SPORE leadership team has implemented several mechanisms to enhance the oversight, and thus activation and accrual, of our SPORE clinical trials, including 1) quarterly accrual report submissions to the Executive Committee (and more frequently should concerns arise); quarterly presentations by the Pis of the SPORE trials to the Executive Committee on accrual progress; annual review of all trials by the Internal and External Advisory Boards; and a requirement to address accrual deficiencies within six-months or risk study closure or replacement. Major SPORE and Core A leadership changes occurred in the fall of 2006, when Dr. Scott M. Lippman succeeded Dr. Waun Ki Hong as SPORE PI and Core A Director and Dr. Rakesh Kumar succeeded Dr. Reuben Lotan as a SPORE Co-Pi and Core A Co-Director (sharing these roles with Dr. Gary L. dayman, who continues a Co-Pi and Co-Director from the previous grant period). The experienced leadership of the HN SPORE will ensure full compliance with all policies and procedures required of NCIand NIH-funded research programs to successfully achieve the SPORE's overall aims.

核心 A 对于 SPORE 的成功至关重要，并为所有 SPORE 项目提供监督和支持 和活动；确保遵守所有一般、政府和国家癌症研究所的规定 (NCI)/美国国立卫生研究院 (NIH) 法规和要求；协调沟通和 与 NCI 项目官员和其他 NCI 工作人员协商准备所有必需的报告，以及 出版物；协调执行委员会所有与 SPORE 相关的会议和通讯， 内部和外部顾问委员会、生物统计和数据管理核心（核心 B）以及 组织采购、病理学和生物标志物核心（核心 C）；和其他关键功能。较上届 拨款期间，核心 A 监督年度预算/再预算的制定、分配和拨款监督 资金;支持执行委员会和顾问委员会定期安排和协调 预定的会议和临时磋商；协调年度征集、评审和颁奖工作 职业发展和发展研究计划的流程；担任主要 联络发展潜在的 InterSPORE 合作并与 NCI SPORE 项目代表进行联络； 并定期与核心董事和项目负责人进行互动，以审查进展情况，确定 问题，并解决阻碍成功实现其目标的问题。过去的试用激活和 HN SPORE 的应计记录是我们之前审查中批评的适当目标；因此， SPORE 领导团队实施了多项机制来加强监督，从而 我们的 SPORE 临床试验的激活和应计，包括 1) 向 执行委员会（如果出现问题，则更频繁）； Pis 的季度报告 SPORE 试验向执行委员会报告应计进展情况；内部和外部部门对所有试验进行年度审查 外部顾问委员会；以及在六个月内解决应计缺陷或风险研究的要求 关闭或更换。 SPORE 和 Core A 领导层的重大变动发生在 2006 年秋天，当时 Dr. Scott M. Lippman 接替 Waun Ki Hong 博士担任 SPORE PI 和核心 A 总监，Rakesh Kumar 博士则接替 接替 Reuben Lotan 博士担任 SPORE Co-Pi 和 Core A 联合总监（与 Gary 博士共享这些角色） L. dayman，继续担任上一个资助期的联合主任和联合主任）。经验丰富的 HN SPORE 的领导层将确保完全遵守 NCI 和要求的所有政策和程序 NIH 资助的研究项目成功实现了 SPORE 的总体目标。